antibodi
therapi
root
thousand
year
ago
earli
form
vaccin
infecti
diseas
develop
china
earli
bc
howev
histori
true
antibodi
therapi
began
centuri
ago
discoveri
serum
anim
immun
toxin
exampl
diphtheria
toxin
virus
effect
therapeut
diseas
caus
agent
human
von
behr
develop
antitoxin
kill
bacteria
neutral
toxin
bacteria
releas
bodi
von
behr
award
first
nobel
prize
medicin
role
discoveri
develop
serum
therapi
diphtheria
emphas
nobel
lectur
serum
therapi
would
possibl
without
prior
work
mostli
loffler
discov
diphtheria
bacilli
roux
reason
diseas
diphtheria
caus
toxin
bacteria
http
birth
therapeut
antibodi
would
possibl
without
paradigm
chang
end
past
centuri
understand
microorgan
toxin
produc
exist
caus
diseas
new
knowledg
combin
develop
time
number
new
methodolog
studi
manipul
microorgan
better
understand
cell
human
physiolog
critic
import
discoveri
first
antibodybas
therapi
call
serum
therapi
whole
serum
blood
immun
anim
use
treatment
howev
exist
antibodi
anticip
von
behr
specif
use
term
antibodi
although
antibodi
isol
character
decad
later
follow
initi
success
late
sera
human
anim
contain
antibodi
wide
use
prophylaxi
therapi
viral
bacteri
diseas
serum
therapi
bacteri
infect
abandon
antibiot
becam
wide
avail
howev
polyclon
antibodi
prepar
use
toxinmedi
infecti
diseas
venom
bite
serum
immunoglobulin
also
use
viral
diseas
treatment
avail
although
immunoglobulin
larg
use
pre
postexposur
prophylaxi
antibodi
product
licens
usa
prevent
treatment
viral
diseas
includ
human
immunoglobulin
use
hepat
measl
virusspecif
polyclon
human
immunoglobulin
cytomegaloviru
hepat
b
rabi
respiratori
syncyti
viru
rsv
vaccinia
varicellazost
human
monoclon
antibodi
mab
synagi
see
also
tabl
polyclon
immunoglobulin
also
use
variou
success
diseas
caus
human
virus
includ
parvoviru
pv
lassa
viru
west
nile
viru
enterovirus
herp
simplex
viru
crimeancongo
hemorrhag
fever
viru
cchfv
junin
viru
sarscov
hiv
treatment
diseas
immun
system
exampl
treatment
primari
immunodefici
disord
associ
defect
humor
immun
see
also
tabl
although
serum
polyclon
antibodi
prepar
clinic
effect
mani
case
problem
relat
toxic
includ
risk
allerg
reaction
lottolot
variat
uncertain
dose
limit
use
addit
activ
antigenspecif
antibodi
polyclon
prepar
typic
repres
rel
small
portion
total
antibodi
rest
antibodi
ineffect
could
even
toxic
immunogen
howev
possibl
produc
larg
amount
antibodi
desir
specif
begin
paradigm
chang
antibodi
began
public
semin
articl
describ
hybridoma
technolog
provid
unlimit
quantiti
mab
predefin
specif
addit
technolog
patent
could
use
freeli
major
limit
hybridoma
technolog
inabl
produc
human
mab
administr
murin
mab
human
result
immun
respons
foreign
protein
gener
human
antimous
antibodi
hama
howev
advent
number
molecular
biolog
techniqu
mostli
recombin
dna
technolog
increas
understand
antibodi
structur
function
led
develop
chimer
human
mab
final
phagedisplay
techniqu
techniqu
base
progress
molecular
biolog
includ
gener
transgen
anim
allow
develop
fulli
human
antibodi
methodolog
extens
review
complet
paradigm
chang
occur
mostli
period
decad
begin
end
wit
fruit
paradigm
chang
result
number
use
therapeut
antibodi
approv
clinic
use
last
decad
howev
last
decad
basic
concept
methodolog
antibodi
gener
chang
significantli
appli
numer
new
target
expect
anoth
paradigm
chang
near
futur
current
use
methodolog
antibodi
develop
base
methodolog
reach
limit
possibl
produc
conceptu
new
antibodi
abl
resolv
longstand
problem
includ
effici
oral
deliveri
penetr
solid
tumor
low
cost
product
major
drawback
antibodi
comparison
small
molecul
perhap
increas
complex
make
multifunct
antibodybas
drug
includ
nanoparticl
conjug
antibodi
variou
format
could
result
novel
therapeut
uniqu
use
properti
briefli
overview
current
state
antibodi
therapeut
tri
answer
question
relat
direct
field
may
follow
futur
indepth
analysi
detail
found
excel
review
total
mab
current
approv
us
fda
clinic
use
almost
treatment
cancer
diseas
relat
immun
system
tabl
april
fda
approv
cimzia
treatment
crohn
diseas
mani
mab
clinic
trial
entri
ongo
complet
clinic
trial
retriev
http
wwwclinicaltrialsgov
search
therapi
mab
march
last
decad
especi
last
year
number
clinic
trial
therapeut
antibodi
increas
dramat
tabl
present
snapshot
clinic
trial
year
howev
increas
larg
due
increas
number
target
indic
antibodi
especi
combin
therapeut
number
target
correspond
antibodi
preclin
develop
discoveri
phase
also
increas
significantli
past
decad
see
eg
latest
largest
meet
molecular
target
cancer
therapeut
octob
san
francisco
http
wwwaacrorg
proport
present
relat
mab
increas
significantli
compar
previou
year
therefor
current
research
develop
mab
potenti
therapeut
grow
mab
market
usher
takeoff
phase
launch
rituxan
rituximab
market
mabthera
europ
nonhodgkin
lymphoma
nhl
rituxan
repres
first
mab
product
succeed
commerci
highrevenuehighgrowth
market
oncolog
provid
signific
enhanc
efficaci
treatment
versu
exist
nonmab
therapi
result
rituxan
rapidli
becam
establish
goldstandard
therapi
nhl
firstlaunch
mab
product
went
achiev
blockbust
statu
revenu
billion
per
year
sever
mab
launch
subsequ
year
also
becam
blockbust
herceptin
remicad
synagi
humira
avastin
six
mab
gener
total
revenu
billion
tabl
mab
gener
billion
total
revenu
mab
revenu
blockbust
mab
steadili
increas
typic
doubledigit
percentag
growth
year
tabl
project
continu
increas
mostli
product
four
establish
compani
top
end
market
genentech
roch
abbott
johnson
johnson
gener
mab
revenu
excess
billion
medimmun
part
astrazeneca
follow
close
addit
tier
four
compani
biogen
idec
amgen
novarti
ucb
pharma
also
evid
forecast
record
absolut
annual
mab
sale
growth
excess
billion
period
dramat
increas
revenu
last
decad
forecast
even
larger
revenu
next
decad
prompt
major
pharmaceut
compani
acquir
number
antibodi
compani
equal
dramat
race
last
sever
year
tabl
andor
creat
antibodi
biolog
depart
today
major
pharmaceut
compani
still
increas
number
smaller
biotech
compani
identifi
develop
novel
antibodybas
therapeut
complet
paradigm
chang
result
convers
mab
promis
therapeut
develop
mostli
biotech
compani
regular
therapeut
import
perhap
case
import
smallmolecul
drug
thu
new
antibodi
therapeut
improv
exist
one
could
clinic
use
expect
develop
larg
compani
biolog
depart
current
differ
antibodybas
candid
therapeut
clinic
trial
target
differ
molecul
see
eg
wwwphrmaorg
biomedicin
clinic
trial
includ
mab
list
least
differ
antibodi
develop
differ
compani
relev
therapeut
target
notabl
except
igfir
target
ten
differ
mab
second
thirdgener
mab
develop
alreadi
valid
target
exampl
base
synagi
antibodi
motavizumab
numax
develop
much
higher
affin
f
protein
rsv
expect
approv
fda
year
ultim
replac
synagi
patent
expir
improv
alreadi
exist
antibodi
also
includ
increas
certain
extent
bind
fc
receptor
enhanc
adcc
halflif
select
appropri
framework
increas
stabil
yield
decreas
immunogen
use
silico
vitro
method
conjug
small
molecul
variou
fusion
protein
enhanc
cytotox
major
lesson
current
state
antibodybas
therapeut
gradual
improv
properti
exist
antibodi
identif
novel
antibodi
novel
target
like
continu
forese
futur
like
major
drive
forc
field
satur
reach
presum
next
decad
two
variou
combin
antibodi
drug
may
domin
unless
major
chang
current
paradigm
occur
rapid
expans
mab
revenu
next
decad
like
driven
number
key
individu
product
record
peak
sale
growth
launch
new
product
furthermor
number
key
mab
product
subject
horizont
indic
broaden
strategi
trend
expect
enhanc
revenu
growth
notabl
exampl
strategi
genentech
roch
avastin
bevacizumab
given
broadspectrum
mode
action
target
angiogenesi
use
across
wide
rang
tumor
type
although
mean
repres
end
mab
market
sale
expans
revenu
growth
may
begin
slow
competit
rival
mab
product
begin
slow
sale
growth
franchis
humira
sale
growth
expens
remicad
exampl
secondgener
product
launch
medimmun
numax
motavizumab
expect
launch
year
rsv
season
cannib
sale
firstgener
mab
product
medimmun
synagi
ultim
organ
revenu
expans
market
finit
prove
case
mab
segment
despit
indic
broaden
opportun
avail
mani
brand
howev
revenu
mab
still
grow
faster
small
molecul
face
unattract
combin
high
exposur
gener
competit
major
focu
area
highest
unmet
need
littl
access
novel
target
space
conspir
make
product
set
slowest
grow
question
whether
new
paradigm
chang
could
trigger
new
dramat
expans
novel
still
unknown
type
therapeut
know
answer
question
surpris
alway
possibl
current
indic
anoth
paradigm
chang
discoveri
biolog
therapeut
come
anytim
soon
rather
appear
gradual
improv
exist
antibodi
identif
antibodi
novel
target
use
current
avail
methodolog
howev
one
area
one
could
expect
conceptu
novel
antibodybas
candid
therapeut
although
within
current
paradigm
go
beyond
tradit
antibodi
structur
see
eg
latest
meet
beyond
antibodi
http
wwwibclifesciencescombeyondoverviewxml
current
almost
fdaapprov
therapeut
antibodi
tabl
except
reopro
lucenti
cimzia
fab
vast
major
clinic
trial
fullsiz
antibodi
mostli
format
size
fundament
problem
larg
molecul
poor
penetr
tissu
eg
solid
tumor
poor
absent
bind
region
surfac
molecul
eg
hiv
envelop
glycoprotein
access
molecul
smaller
size
therefor
larg
amount
work
especi
last
decad
aim
develop
novel
scaffold
much
smaller
size
higher
stabil
see
eg
recent
review
scaffold
base
variou
human
nonhuman
molecul
high
stabil
could
divid
two
major
group
purpos
review
antibodyderiv
other
briefli
discuss
antibodyderiv
scaffold
specif
deriv
antibodi
domain
exampl
potenti
use
candid
therapeut
excel
recent
review
describ
second
group
first
two
domain
antibodi
dab
enter
clinic
trial
phase
last
year
one
camelid
dab
target
von
willebrand
factor
vwf
small
size
camelid
dab
also
term
nanobodi
compani
ablynx
develop
neutral
vwf
could
reduc
risk
thrombosi
patient
acut
coronari
syndrom
ac
thrombot
thrombocytopen
purpura
ttp
ablynx
report
result
phase
studi
decemb
http
wwwablynxcom
dab
human
protein
target
preclin
studi
demonstr
potenc
level
least
equival
marketlead
antitnf
drug
anim
model
rheumatoid
arthriti
phase
clinic
trial
show
drug
welltoler
healthi
volunt
success
complet
novemb
march
biotechnolog
compani
arana
therapeut
limit
http
wwwaranacom
develop
antibodi
announc
commenc
recruit
phase
ii
trial
psoriasi
success
compani
plan
initi
phase
iii
trial
antibodi
licens
domanti
http
wwwdomantiscom
wholli
own
subsidiari
gsk
mani
addit
dab
earli
stage
develop
featur
dab
make
attract
candid
therapeut
firstli
size
kda
order
magnitud
smaller
size
kda
small
size
lead
rel
good
penetr
tissu
abil
bind
caviti
activ
site
protein
target
may
access
fullsiz
antibodi
could
particularli
import
develop
therapeut
rapidli
mutat
virus
exampl
hiv
virus
evolv
human
escap
natur
occur
antibodi
larg
size
surfac
region
critic
viral
life
cycl
may
vulner
target
molecul
smaller
size
includ
dab
secondli
dab
may
stabl
fullsiz
antibodi
circul
rel
easili
engin
increas
stabil
exampl
dab
increas
stabil
could
taken
oral
deliv
via
pulmonari
rout
may
even
penetr
barrier
retain
activ
even
subject
harsh
condit
freezedri
heat
denatur
addit
dab
typic
monomer
high
solubl
significantli
aggreg
engin
reduc
aggreg
halflif
circul
rel
easili
adjust
minut
hour
week
contrast
convent
antibodi
dab
well
express
bacteri
yeast
mammalian
cell
system
final
small
size
dab
allow
higher
molar
quantiti
per
gram
product
provid
signific
increas
potenc
per
dose
reduct
overal
manufactur
cost
http
wwwdomantiscom
research
novel
antibodyderiv
scaffold
continu
identifi
vhbase
scaffold
stabl
highli
solubl
use
construct
larges
clone
dab
phage
librari
graft
five
fab
librari
randomli
mutagen
pan
librari
hiv
env
complex
result
identif
potent
broadli
crossreact
dab
hiv
neutral
primari
hiv
isol
differ
clade
low
rang
recent
one
author
dsd
propos
use
engin
antibodi
constant
domain
igg
iga
igd
ige
igm
scaffold
construct
librari
small
size
domain
role
antibodi
effector
function
term
nanoantibodi
smallest
fragment
could
engin
exhibit
simultan
antigenbind
effector
function
sever
larg
librari
clone
construct
antigenspecif
binder
success
identifi
xiao
vu
dimitrov
et
al
prepar
possibl
novel
scaffold
develop
could
provid
new
opportun
identif
potenti
use
therapeut
rapid
progress
made
last
decad
toward
develop
potent
therapeut
antibodi
mostli
cancer
immun
diseas
rais
number
question
futur
direct
field
key
question
whether
indic
paradigm
chang
could
lead
radic
differ
therapeut
occur
decad
ago
result
explos
antibodi
therapeut
approv
clinic
use
last
decad
histori
provid
answer
paradigm
shift
occur
probabl
take
decad
wit
fruition
shift
term
new
licens
antibodi
therapeut
meanwhil
gradual
improv
characterist
exist
antibodi
discoveri
novel
antibodi
novel
target
combin
antibodi
conjug
drug
nanoparticl
reagent
go
beyond
antibodi
develop
novel
antibodybas
scaffold
superior
properti
alreadi
use
major
area
research
develop
come
decad
decad
like
see
mani
antibodybas
therapeut
base
differ
scaffold
approv
clinic
use
hundr
preclin
clinic
develop
